Bliss GVS Pharma Limited
NSE: BLISSGVS BSE: BLISSGVS
NSE
152.98
0.52 (0.34%)
Prev Close
152.46
Open Price
152.79
Volume
339,504
Today Low / High
150.2 / 154
52 WK Low / High
106.04 / 190.97
Range
145 - 161
BSE
153.00
0.20 (0.13%)
Prev Close
152.8
Open Price
155.4
Volume
33,012
Today Low / High
150.5 / 155.4
52 WK Low / High
105.05 / 190.65
Range
145 - 161
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 152.98 (target range: 145 - 161), reflecting a change of 0.52 (0.34107%). On the BSE, it is listed at 153 (target range: 145 - 161), showing a change of 0.2 (0.13089%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
01 Oct
152.79
0.12%
30 Sep
147.38
3.45%
29 Sep
145.15
1.54%
26 Sep
145.02
-0.16%
25 Sep
151.90
-2.82%
24 Sep
151.65
-0.06%
23 Sep
151.00
0.15%
22 Sep
151.00
0.34%
19 Sep
154.50
-2.57%
18 Sep
154.40
-0.60%
17 Sep
152.79
0.01%
16 Sep
151.41
-0.01%
15 Sep
152.69
-0.84%
12 Sep
154.48
-1.29%
11 Sep
153.80
-0.22%
10 Sep
153.90
-0.78%
09 Sep
153.00
0.57%
08 Sep
155.89
-1.03%
05 Sep
156.95
-0.67%
04 Sep
159.95
-2.34%
03 Sep
160.40
-1.08%
Bliss GVS Pharma Limited Graph
Bliss GVS Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Bliss GVS Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 152.98, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 153.00 | 154.53 | 139.08 - 169.98 |
| 156.06 | 124.85 - 187.27 | ||
| 157.59 | 110.31 - 204.87 | ||
| Bearish Scenario | 153.00 | 151.47 | 136.32 - 166.62 |
| 149.94 | 119.95 - 179.93 | ||
| 148.41 | 103.89 - 192.93 |
Overview of Bliss GVS Pharma Limited
ISIN
INE416D01022
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
906,652
Market Cap
16,162,256,227
Last Dividend
0.5
Official Website
IPO Date
2010-07-26
DCF Diff
8.23
DCF
144
Financial Ratios Every Investor Needs
Stock Dividend of BLISSGVS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-24 | July 24, 25 | 0.5 | 0.5 | 2025-07-24 | 2025-08-30 | |
| 2024-07-18 | July 18, 24 | 0.5 | 0.5 | 2024-07-18 | 2024-08-24 | |
| 2023-07-12 | July 12, 23 | 0.5 | 0.5 | 2023-07-12 | 2023-08-18 | |
| 2022-06-20 | June 20, 22 | 0.5 | 0.5 | 2022-06-21 | 2022-07-28 | |
| 2021-09-13 | September 13, 21 | 0.5 | 0.5 | 2021-09-14 | 2021-10-20 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 809.73 Cr | 413.69 Cr | 396.04 Cr | 0.4891 | 17.37 Cr | 9.79 Cr | 283.99 Cr | 84.30 Cr | 8.02 | 126.68 Cr | 0.1041 |
| 2024-03-31 | 765.91 Cr | 516.48 Cr | 249.43 Cr | 0.3257 | 15.23 Cr | 8.41 Cr | 123.10 Cr | 75.45 Cr | 7.23 | 148.81 Cr | 0.0985 |
| 2023-03-31 | 751.59 Cr | 401.32 Cr | 350.26 Cr | 0.4660 | 21.79 Cr | 7.28 Cr | 98.65 Cr | 70.86 Cr | 6.83 | 135.11 Cr | 0.0943 |
| 2022-03-31 | 737.93 Cr | 390.98 Cr | 346.95 Cr | 0.4702 | 21.38 Cr | 8.88 Cr | 101.32 Cr | 15.04 Cr | 1.46 | 76.24 Cr | 0.0204 |
| 2021-03-31 | 568.69 Cr | 328.91 Cr | 239.78 Cr | 0.4216 | 10.40 Cr | 6.97 Cr | 89.45 Cr | 68.49 Cr | 6.64 | 126.87 Cr | 0.1204 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 213.31 Cr | 1,300.84 Cr | 208.99 Cr | 1,050.3756 Cr | 88.10 Cr | -125.20 Cr | 125.73 Cr | 417.72 Cr | 0.00 Cr | 0.05 Cr | 4.38 Cr | 171.7170 Cr |
| 2024-03-31 | 23.14 Cr | 1,213.87 Cr | 210.89 Cr | 967.1933 Cr | 99.84 Cr | 76.70 Cr | 118.45 Cr | 369.38 Cr | 6.92 Cr | 0.06 Cr | 8.02 Cr | 159.8210 Cr |
| 2023-03-31 | 24.96 Cr | 1,156.85 Cr | 239.43 Cr | 883.8969 Cr | 101.90 Cr | 76.94 Cr | 103.06 Cr | 372.91 Cr | 42.06 Cr | 0.07 Cr | 56.86 Cr | 193.2590 Cr |
| 2022-03-31 | 21.92 Cr | 1,108.75 Cr | 262.28 Cr | 818.7017 Cr | 109.39 Cr | 87.48 Cr | 123.94 Cr | 294.82 Cr | 57.71 Cr | 0.09 Cr | 3.68 Cr | 233.0862 Cr |
| 2021-03-31 | 12.63 Cr | 1,076.79 Cr | 248.88 Cr | 808.2534 Cr | 121.90 Cr | 109.26 Cr | 98.93 Cr | 227.82 Cr | 41.79 Cr | 0.10 Cr | 62.01 Cr | 203.6358 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 105.9129 Cr | -75.4409 Cr | -30.3446 Cr | 29.8476 Cr | 0.2261 Cr | 23.8167 Cr | -76.0653 Cr | 84.2993 Cr | -16.4736 Cr | -5.4487 Cr | -30.4542 Cr |
| 2024-03-31 | 152.4486 Cr | -132.8218 Cr | -20.8930 Cr | 124.1193 Cr | -1.4163 Cr | 23.5906 Cr | -28.3293 Cr | 75.4541 Cr | -8.8958 Cr | -5.3949 Cr | -22.4218 Cr |
| 2023-03-31 | 34.3135 Cr | -7.7509 Cr | -24.9385 Cr | -59.4855 Cr | 3.0198 Cr | 25.0069 Cr | -93.7990 Cr | 106.0716 Cr | -13.8732 Cr | -5.4372 Cr | 15.0032 Cr |
| 2022-03-31 | 135.4806 Cr | -92.9751 Cr | -23.7301 Cr | 61.4775 Cr | 8.8526 Cr | 21.9871 Cr | -74.0031 Cr | 127.7598 Cr | -15.6057 Cr | -5.3265 Cr | -29.0968 Cr |
| 2021-03-31 | 63.9694 Cr | -46.9910 Cr | -20.7980 Cr | 54.8452 Cr | -2.2050 Cr | 13.1345 Cr | -9.1242 Cr | 104.1270 Cr | -8.9288 Cr | -5.5495 Cr | -26.8011 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 207.47 Cr | 91.89 Cr | 115.58 Cr | 0.5571 | 33.13 Cr | 43.04 Cr | 4.08 | 76.78 Cr | 0.2074 |
| 2025-03-31 | 197.99 Cr | 99.43 Cr | 98.56 Cr | 0.4978 | 70.31 Cr | 15.54 Cr | 1.47 | 33.15 Cr | 0.0785 |
| 2024-12-31 | 210.42 Cr | 114.20 Cr | 96.22 Cr | 0.4573 | 22.24 Cr | 23.80 Cr | 2.27 | 45.05 Cr | 0.1131 |
| 2024-09-30 | 217.68 Cr | 149.41 Cr | 68.27 Cr | 0.3136 | 34.50 Cr | 24.26 Cr | 2.31 | 46.51 Cr | 0.1115 |
| 2024-06-30 | 183.64 Cr | 118.53 Cr | 65.12 Cr | 0.3546 | 27.48 Cr | 20.70 Cr | 1.97 | 38.45 Cr | 0.1127 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 213.31 Cr | 117.57 Cr | 213.31 Cr | 447.28 Cr | 125.73 Cr | 826.51 Cr | 417.72 Cr | 1,300.84 Cr | 208.99 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 219.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,048.04 Cr |
| 2024-09-30 | 33.11 Cr | 199.92 Cr | 233.03 Cr | 428.37 Cr | 131.41 Cr | 851.41 Cr | 379.18 Cr | 1,282.51 Cr | 234.46 Cr |
| 2024-06-30 | -140.37 Cr | 280.73 Cr | 140.37 Cr | 0.00 Cr | 0.00 Cr | 140.37 Cr | 0.00 Cr | 0.00 Cr | -1,002.98 Cr |
| 2024-03-31 | 215.62 Cr | 0.56 Cr | 216.17 Cr | 414.93 Cr | 118.45 Cr | 811.62 Cr | 369.38 Cr | 1,213.87 Cr | 210.89 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 15.54 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 23.80 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 24.26 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 20.70 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | -9.15 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,636.20 | ₹3,925,785,949,961.00 | ₹3,109,028.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹5,710.00 | ₹1,515,830,342,520.00 | ₹721,664.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,565.40 | ₹1,206,691,803,000.00 | ₹300,672.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,244.70 | ₹1,036,053,739,575.00 | ₹4,082,857.00 |
| Mankind Pharma Limited | MANKIND | ₹2,440.00 | ₹1,007,130,715,600.00 | ₹218,700.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹994.00 | ₹1,000,192,183,634.00 | ₹560,964.00 |
| Lupin Limited | LUPIN | ₹1,981.30 | ₹904,968,681,500.00 | ₹2,121,417.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,459.50 | ₹652,765,117,500.00 | ₹177,737.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,086.00 | ₹630,750,562,578.00 | ₹1,043,306.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,959.20 | ₹552,887,824,993.00 | ₹524,801.00 |
| Laurus Labs Limited | LAURUSLABS | ₹872.00 | ₹470,727,311,928.00 | ₹2,073,317.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,327.30 | ₹336,741,608,551.00 | ₹253,514.00 |
| Cohance Lifesciences Limited | COHANCE | ₹870.50 | ₹333,024,695,370.00 | ₹176,686.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,398.20 | ₹299,620,613,477.00 | ₹59,582.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,689.70 | ₹264,600,665,038.00 | ₹140,607.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,492.80 | ₹242,557,310,933.00 | ₹804,577.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,222.00 | ₹230,550,000,000.00 | ₹17,995.00 |
| Eris Lifesciences Limited | ERIS | ₹1,624.90 | ₹221,333,403,895.00 | ₹66,608.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,386.00 | ₹197,400,672,154.00 | ₹76,750.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹904.30 | ₹177,752,033,033.00 | ₹38,869.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,113.00 | ₹176,467,022,592.00 | ₹116,056.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,058.50 | ₹156,470,076,216.00 | ₹85,382.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹806.55 | ₹144,461,065,649.00 | ₹369,545.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹542.65 | ₹131,670,612,487.00 | ₹2,904,200.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,302.00 | ₹104,609,305,364.00 | ₹8,422.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹778.75 | ₹76,154,669,605.00 | ₹110,903.00 |
| Strides Pharma Science Limited | STAR | ₹819.15 | ₹75,503,278,673.00 | ₹223,057.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹829.10 | ₹75,143,794,598.00 | ₹230,230.00 |
| FDC Limited | FDC | ₹457.30 | ₹74,453,051,413.00 | ₹74,687.00 |
| Innova Captab Limited | INNOVACAP | ₹872.30 | ₹49,917,305,567.00 | ₹25,306.00 |
| Sequent Scientific Limited | SEQUENT | ₹194.90 | ₹48,708,014,270.00 | ₹626,582.00 |
| Suven Life Sciences Limited | SUVEN | ₹207.05 | ₹45,145,326,314.00 | ₹112,355.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹488.05 | ₹44,544,323,500.00 | ₹58,510.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹132.15 | ₹42,885,527,854.00 | ₹193,124.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,264.80 | ₹37,457,561,172.00 | ₹5,746.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹720.15 | ₹36,525,363,466.00 | ₹24,749.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹351.15 | ₹35,214,201,982.00 | ₹25,077.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹482.40 | ₹33,963,733,800.00 | ₹20,154.00 |
| Hikal Limited | HIKAL | ₹255.00 | ₹31,441,691,250.00 | ₹129,465.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹106.99 | ₹31,404,508,295.00 | ₹3,421,704.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹48.81 | ₹26,745,620,048.00 | ₹2,029,317.00 |
| Indoco Remedies Limited | INDOCO | ₹290.15 | ₹26,740,631,661.00 | ₹21,520.00 |
| Alembic Limited | ALEMBICLTD | ₹103.45 | ₹26,564,080,107.00 | ₹495,596.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹605.35 | ₹25,889,578,533.00 | ₹127,415.00 |
Key Executives
Compliance Officer, Company Secretary & Nodal Officer
Ms. Aditi Himanshu Bhatt
Gender: female
Year Born:
Associate Vice President
Mr. Sourya Das
Gender: male
Year Born:
Executive & Whole Time Director
Ms. Shruti N. Vishal Rao
Gender: female
Year Born: 1985
Vice President of Technical Operations
Mr. Prashant Churi
Gender: male
Year Born:
Chief Financial Officer
Mr. Deepak B. Sawant
Gender: male
Year Born: 1980
Executive & Whole Time Director
Dr. Vibha Gagan Sharma
Gender: Not Specified
Year Born: 1983
MD & Director
Mr. Gagan Harsh Sharma
Gender: male
Year Born: 1983
FAQs about Bliss GVS Pharma Limited
Who is the CEO of the company?
The CEO is Gagan Harsh Sharma.
What is the current market price of the stock?
The current price is ₹152.98.
What is the 52-week price range?
The range is ₹106.04-190.97.
What is the market capitalization of the company?
The market capitalization is ₹1,616.23 crores.
What is the dividend yield?
The dividend yield is 0.33%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 15.13.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Bliss GVS Pharma Limited (ISIN: INE416D01022) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹1,616.23 crores and an average daily volume of 906,652 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.5.